

Ogawa, Katelyn

From: Richard A. Van Etten, MD, PhD, Director, Chao Family Comprehensive Cancer Center
<hsmarcom@uci.edu>
Sent: Tuesday, December 21, 2021 7:00 AM
To: Ogawa, Katelyn
Subject: Cancer clinical trials open to patients

UCI Health

Chao Family
Comprehensive Cancer Center

Cancer Clinical Trials

These featured cancer clinical trials are currently open at the UCI Health Chao Family Comprehensive Cancer Center.

To refer a patient or get more information about a clinical trial, click on the principal investigator's name to send an email. You may also contact us at ucstudy@uci.edu or [877-UC-Study](tel:877-UC-Study). To search all cancer clinical trials now available at UCI Health, visit cancer.uci.edu/clinical-trials-flowcharts

Brain and nervous system

A phase 2, single-arm study of NovoTTF-200A in bevacizumab-naive subjects with recurrent WHO grade 3 malignant astrocytoma (UCI 16-56/NovoTTF-200a)

For more information, contact principal investigator Daniela Bota, MD

A phase 2 study of the PARP inhibitor olaparib (AZD2281) in IDH1 and IDH2 mutant advanced solid tumors (ETCTN-10129)

For more information, contact principal investigator Xiao-Tang Kong, MD

Breast

A phase 2 trial of radium-223 dichloride in combination with paclitaxel in patients with metastatic breast cancer that has spread to the bones (ETCTN-10302)

For more information, contact principal investigator Ritesh Parajuli, MD

A phase 1b/2, two-part, open-label study to assess the safety and antitumor activity of

zanidatamab in combination with ALX148 in advanced HER2-expressing cancer (UCI 21-57/ZWI-ZW25-204)

For more information, contact principal investigator Ritesh Parajuli, MD

COVID-19

NCI COVID-19 in Cancer Patients Study (NCCAPS): a longitudinal natural history study (NCICOVID)

For more information, contact principal investigator Hannah Hyochan Nam, MD

Gastrointestinal

A phase 2 study of neoadjuvant nivolumab plus ipilimumab and short-course radiation in MSI-H/dMMR locally advanced rectal adenocarcinoma (EA2201)

For more information, contact principal investigator May Cho, MD

A phase 2, randomized study of de-intensified chemoradiation for early-stage anal squamous cell carcinoma (DECREASE) (EA2182)

For more information, contact principal investigator Jason Zell, DO

Genitourinary

A phase 3 study of CG0070 in patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG) (UCI 20-210/CG3002S)

For more information, contact principal investigator Edward Uchio, MD

A master protocol evaluating the safety and efficacy of therapies for metastatic, castration-resistant prostate cancer (mCRPC) (UCI 21-07/20190505)

For more information, contact principal investigator Arash Rezazadeh Kalebasty, MD

A phase 2, randomized trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer, where cisplatin-based treatment is not an option (ETCTN-10100)

For more information, contact principal investigator Nataliya Mar, MD

Gynecologic oncology

A phase 2, randomized study of bevacizumab and either weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or platinum-refractory ovarian cancer (ETCTN-10150)

For more information, contact principal investigator Jill Tseng, MD

A phase 2, open-label, single-arm study of the efficacy and safety of the WEE1 inhibitor ZN-c3 as second-line, oral therapy in adult women with recurrent or persistent uterine serous carcinoma (USC) (UCI 20-203/ZN-c3-004)

For more information, contact principal investigator Krishnansu Tewari, MD

Head and neck

Randomized phase 2 and phase 3 studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA) (HN001)

For more information, contact principal investigator Rupali Nabar, MD

A randomized phase 2/3 trial of adjuvant radiation therapy with cisplatin and docetaxel-cetuximab or cisplatin-atezolizumab in pathologic, high-risk squamous cell cancer of the head and neck (RTOG-1216)

For more information, contact principal investigator Rupali Nabar, MD

Hematologic malignancies

The PRIME trial: PARP inhibition in IDH mutant effectiveness trial. A phase 2 study of olaparib in isocitrate dehydrogenase (IDH) mutant relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome (ETCTN-10264)

For more information, contact principal investigator Deepa Jeyakumar, MD

A phase 2 study of Descartes-08 consolidation treatment in patients with high-risk multiple myeloma who have residual disease after induction therapy (UCI 21-02/DC-08-B)

For more information, contact principal investigator Stefan O. Ciurea, MD

Hepatobiliary

A phase 1/2 study of M3814 (peposertib) in combination with hypofractionated radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma (ETCTN-10366)

For more information, contact principal investigator Farshid Dayyani, MD

A phase 2, open-label, single-arm study to treat patients with refractory metastatic colorectal cancer and non-small cell lung cancer with liver metastasis using a

combination of trans-arterial tirapazamine embolization (TATE) and pembrolizumab (UCI 21-39/LT-007)

For more information, contact principal investigator Nadine Abi-Jaoudeh, MD

Lung

A phase 1/1b, open-label, dose-escalation and expansion study of SBT6050 alone and in combination with pembrolizumab in subjects with HER2-expressing or advanced solid tumors (UCI 20-185/SBT6050-101)

For more information, contact principal investigator Sai-Hong Ou, MD

A phase 1/2 study of the highly selective ROS1 inhibitor NUV-520 in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors (UCI 21-47/NUV-520)

For more information, contact principal investigator Sai-Hong Ou, MD

Skin

A phase 1/2 study of dabrafenib, trametinib and navitoclax in BRAF-mutant melanoma (phase 1 and 2) and other solid tumors (phase 1 only) (ETCTN-9466)

For more information, contact principal investigator Justin Moyers, MD

A phase 2, open-label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy (UCI 19-104/4SC-202-3-2018 MERKLIN-2)

For more information, contact principal investigator Ling Gao, MD



Chao Family Comprehensive Cancer Center

As an NCI-designated comprehensive cancer center, the UCI Chao Family Comprehensive Cancer Center conducts many clinical trials. By participating in a clinical trial, your patients have access to leading-edge treatments and therapies long before they are available to the general public. According to the National Comprehensive Cancer Network (NCCN) guidelines, the best management for any cancer patient is on a clinical trial.

UCI Health | Chao Family Comprehensive Cancer Center | NCI

UCI Medical Center | 101 The City Drive South | Orange, CA 92868

